Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02979899 · ClinicalTrials.gov registry record · Phase 3
Trial of TRC105 and Pazopanib Versus Pazopanib Alone in Patients With Advanced Angiosarcoma
A Phase 3 study of Advanced Angiosarcoma, sponsored by Tracon Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 128
- Enrollment target
- 20
- Study locations
NCT02979899 is a Phase 3 study of Advanced Angiosarcoma that has completed, run by Tracon Pharmaceuticals. The registered enrollment target is 128 participants. The trial reports 20 study locations across 14 states.
The verdict
NCT02979899, a Phase 3 study of Advanced Angiosarcoma, has completed, sponsored by Tracon Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 128 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a study of TRC105 in combination with standard dose pazopanib compared to single agent pazopanib in patients with angiosarcoma not amenable to curative intent surgery (e.g., metastatic or bulky disease, and disease for which surgical resection would carry an unacceptable risk to the patient) who have not received pazopanib or TRC105 previously.
Conditions Studied
Interventions
- BIOLOGICAL TRC105
- DRUG Votrient
Study Locations (20)
New York
- Roswell Park Cancer Institute - Buffalo
- Northwell Health - Lake Success
- MSKCC - New York
California
- Stanford University - Palo Alto
- Sarcoma Oncology Center - Santa Monica
Florida
- Mayo Clinic Jacksonville - Jacksonville
- Moffitt Cancer Center - Tampa
Massachusetts
- Massachusetts General Hospital - Boston
- Dana Farber Cancer Institute - Boston
Ohio
- Cleveland Clinic - Cleveland
- Ohio State University - Columbus
Arizona
- University of Arizona Cancer Center - Tucson
Colorado
- University of Colorado Denver - Aurora
Georgia
- Northside Hospital - Sandy Springs
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 128 participants |
| Start Date | 2017-02-13 |
| Est. Completion | 2019-08-31 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02979899
The ClinicalTrials.gov registry entry for NCT02979899 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 128 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Tracon Pharmaceuticals, which has 16 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Advanced Angiosarcoma appearing as the primary indexed condition, and to 2 interventions - of which TRC105 is the first listed.
NCT02979899 reports 20 study locations spanning 14 distinct geographic areas - top geographies include New York, California, Florida.
Frequently Asked Questions
What is clinical trial NCT02979899 about?
NCT02979899 is a clinical study titled "Trial of TRC105 and Pazopanib Versus Pazopanib Alone in Patients With Advanced Angiosarcoma". This is a study of TRC105 in combination with standard dose pazopanib compared to single agent pazopanib in patients with angiosarcoma not amenable to curative intent surgery (e.g., metastatic or bulky disease, and disease for which surgical resection would carry an unacceptable risk to the patient)...
What is the current status of trial NCT02979899?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 128 participants. The study started on 2017-02-13. Estimated completion is 2019-08-31.
What conditions does trial NCT02979899 study?
This clinical trial studies the following conditions: Advanced Angiosarcoma.
What interventions are being tested in trial NCT02979899?
The interventions under investigation include: TRC105 (BIOLOGICAL), Votrient (DRUG).
Who is sponsoring clinical trial NCT02979899?
This trial is sponsored by Tracon Pharmaceuticals, which has 16 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02979899 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.